UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
000-49908 SEC FILE NUMBER
CUSIP NUMBER
(Check one) [X] Form 10-K [_] Form 20-F [_] Form 11-K [_] Form 10-Q
[_] Form N-SAR Form N-CSR
For Period Ended: May 31, 2004
[_] Transition Report on Form 10-K
[_] Transition Report on Form 20-F
[_] Transition Report on Form 11-K
[_] Transition Report on Form 10-Q
[_] Transition Report on Form N-SAR
For the Period Ended _____________
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
PART I- REGISTRANT INFORMATION
CytoDyn, Inc
________________________________________________________________________________
Full Name of Registrant
Rexray Corporation
________________________________________________________________________________
Former Name if Applicable
200 De Vargas Street, Suite 1
Santa Fe, New Mexico 87501
________________________________________________________________________________
Address of Principal Executive Office
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
by completed. (Check box if appropriate) [X]
(a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense.
(b) The annual report on Form 10-KSB or a portion thereof, will be filed on
or before the fifteenth calendar day following the prescribed due date.
(c) The accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
PART III - NARRATIVE
State below in reasonable detail the reason why Form 10-K, 20-F, 11-K, 10-Q,
N-SAR, N-CSR, or the transition report or portion thereof, could not be filed
within the prescribed period.
CytoDyn, Inc. has, during the fiscal year ended May 31, 2004, effected a change
of control of the former Rexray Corporation through the acquisition of certain
assets from CytoDyn of New Mexico, Inc. in exchange for stock of CytoDyn, Inc.
The financial statements of CytoDyn, Inc. are required to be augmented by
additional financial statements reflecting the financial information of CytoDyn
of New Mexico, Inc. CytoDyn of New Mexico, Inc.'s financials had not been
audited, and, therefore, CytoDyn Inc.'s financials for this report have taken
longer to prepare than expected and could not be completed without unreasonable
expense and effort.
PART IV- OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Corinne E. Allen, Vice President of Business Development
Telephone number: 505-988-5520
(2) Have all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter
period that the registrant was required to file such reports been
filed? If answer is no, identify reports.
[X] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject
report or portion thereof? [ ] Yes [ X] No If so, attach an explanation
of the anticipated change, both narratively and quantitatively, and, if
appropriate, state the reasons why a reasonable estimate of the results
cannot be made.
CytoDyn, Inc.
Has caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: August 30, 2004 By: /s/ Allen D. Allen
----------------- ---------------------